Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 1/20 | 0.67 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | FABP6 | P51161 | 1/20 | 0.42 |
| ▸ | APOB | P04114 | 1/20 | 0.42 |
| ▸ | MTTP | P55157 | 1/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28749005 | 0.87 | FYN (0.56) | FYNGRIN2BMEN1KMT2AHDAC1 | |
| SCHEMBL3834622 | 0.81 | GRIN2B (0.77) | FYNGRIN2BDRD2DRD3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL10446804 | 0.79 | GRIN2B (0.74) | FYNGRIN2BDRD2DRD3SIGMAR1 | |
| SCHEMBL865974 | 0.79 | FYN (0.69) | FYNGRIN2BDRD2DRD3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL10447028 | 0.78 | FYN (0.63) | FYNGRIN2BDRD2BCHEACHE | |
| SCHEMBL8186614 | 0.74 | GRIN2B (0.73) | FYNGRIN2BBCHEACHEBACE1 | |
| Hydrochloric Acid SCHEMBL8187663 | 0.73 | GRIN2B (0.71) | FYNGRIN2BBCHEACHEBACE1 | |
| SCHEMBL867108 | 0.71 | FYN (0.54) | FYNGRIN2BDRD2DRD3BCHE | |
| SCHEMBL5358231 | 0.71 | GRIN2B (0.58) | FYNGRIN2BDRD2DRD3SIGMAR1 | |
| SCHEMBL5373232 | 0.71 | ACHE (0.58) | FYNGRIN2BDRD2DRD3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3247693-B1 | PROCESS FOR THE PREPARATION OF INDANAMINE DERIVATIVES AND NEW SYNTHESIS INTERMEDIATES | OLON SPA (IT) | 2019-09-04 | — | — | EP | disclosed |
| US-20170362161-A1 | PROCESS FOR THE PREPARATION OF INDANAMINE DERIVATIVES AND NEW SYNTHESIS INTERMEDIATES | OLON S.P.A. (IT) | 2017-12-21 | — | — | US | disclosed |
| US-20170362161-A1 | PROCESS FOR THE PREPARATION OF INDANAMINE DERIVATIVES AND NEW SYNTHESIS INTERMEDIATES | OLON S.P.A. (IT) | 2017-12-21 | — | — | US | disclosed |
| CN-104379566-B | QAB-149 intermediate and the synthetic method of QAB-149 | 上海威智医药科技有限公司 | 2016-08-24 | — | — | CN | disclosed |
| WO-2016116857-A1 | PROCESS FOR THE PREPARATION OF INDANAMINE DERIVATIVES AND NEW SYNTHESIS INTERMEDIATES | LABORATORIO CHIMICO INTERNAZIONALE S.P.A. (IT) | 2016-07-28 | — | — | WO | disclosed |
| US-9040559-B2 | BETA2-adrenoceptor agonists | NOVARTIS AG (CH) | 2015-05-26 | — | — | US | disclosed |
| US-20140343091-A1 | BETA2-ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2014-11-20 | — | — | US | disclosed |
| US-8796307-B2 | Beta2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2014-08-05 | — | — | US | disclosed |
| US-20140066478-A1 | Beta2-Adrenoreceptor Agonists | NOVARTIS AG (CH) | 2014-03-06 | — | — | US | disclosed |
| US-8658673-B2 | BETA2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2014-02-25 | — | — | US | disclosed |
| US-7820694-B2 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20100029705-A1 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | CUENOUD BERNARD | 2010-02-04 | — | — | US | disclosed |
| US-7622483-B2 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | NOVARTIS AG (CH) | 2009-11-24 | — | — | US | disclosed |
| EP-1183240-B1 | BETA2-ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20050153957-A1 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | NOVARTIS AG (CH) | 2005-07-14 | — | — | US | disclosed |
| US-6878721-B1 | N-(partially hydrogenated fused carbocycle)-2-arylethylamine derivatives, e.g., 8-hydroxy-5-(1-hydroxy-2-(indan-2-ylamino)-ethyl)-1H-quinolin-2-one; treatment of obstructive or inflammatory | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| CN-1156451-C | Betz 2-adrenoceptor agonists | ��˹��ŵ�� | 2004-07-07 | — | — | CN | disclosed |
| CN-1353692-A | Betz 2-adrenoceptor agonists | NOVARTIS AG (CH) | 2002-06-12 | — | — | CN | disclosed |
| EP-1183240-A1 | BETA2-ADRENOCEPTOR AGONISTS | Novartis AG (CH) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000075114-A1 | BETA2-ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066478-A1 | Beta2-Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | FYN 2642/4885GRIN2B 569/4885DRD2 248/4885 |
| US-20170362161-A1 | PROCESS FOR THE PREPARATION OF INDANAMINE DERIVATIVES AND NEW SYNTHESIS INTERMEDIATES | CYP3A5, SQLE, CYP3A4 | FYN 1318/4885GRIN2B 3348/4885DRD2 686/4885 |
| US-20140343091-A1 | BETA2-ADRENOCEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | FYN 2482/4885GRIN2B 866/4885DRD2 121/4885 |
| US-20050153957-A1 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | ADRB3, ADRB2, ADRB1 | FYN 2559/4885GRIN2B 1156/4885DRD2 12/4885 |
| US-20100029705-A1 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | ADRB3, ADRB2, ADRB1 | FYN 2559/4885GRIN2B 1156/4885DRD2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.